PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Clinical trial NCT00838760 · COMPLETED
Trial details
- NCT number
- NCT00838760
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2009-10-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.